NCT07865377

Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation

← Centro de ensayos clínicos

Campos del registro

Estado general
RECRUITING
Condiciones
Coronary Artery Disease (CAD), Menopause, Hormones
Tipo de estudio
INTERVENTIONAL
Fase
NA
Objetivo principal
PREVENTION
Tipo de intervención
DIETARY_SUPPLEMENT, OTHER
Intervenciones
Trans-resveratrol, 1000 mg daily for 90 days, Placebo
Patrocinador principal
InCor Heart Institute (OTHER)

En caché: 2026-10-09 02:19:05

Ver en ClinicalTrials.gov

Resumen breve

Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.

Contacto

¿Necesita un informe o redacción médica basada en este ensayo?